Literature DB >> 8381382

Analysis of hepatitis C virus RNA prevalence and surrogate markers of infection among seropositive voluntary blood donors.

J M Romeo1, P P Ulrich, M P Busch, G N Vyas.   

Abstract

A novel reverse transcription polymerase chain reaction assay has been developed that uses drop-in-drop-out primers for the heminested amplification of hepatitis C virus complementary DNA. This assay has been used for analysis of the prevalence of hepatitis C virus RNA in a set of 53 plasma specimens from blood donations that were repeatedly reactive for hepatitis C virus antibodies with the first-generation enzyme immunoassay. Of 21 specimens that were also reactive for hepatitis C virus antibodies by a four-antigen recombinant immunoblot assay (recombinant immunoblot assay 2), 20 (95%) contained detectable levels of hepatitis C virus RNA. Cryoprecipitate in three specimens reactive in the recombinant immunoblot assay led to an apparent failure of detecting hepatitis C virus RNA, but repeat tests of redissolved cryoprecipitate subsequently revealed hepatitis C virus RNA. Hepatitis C virus RNA was also detected in plasma from 5 of 29 donors nonreactive by recombinant immunoblot assay. However, evidence of viremia in these donors could not be confirmed on follow-up specimens collected more than 1 yr later. Our results demonstrate that the presence of recombinant immunoblot assay reactivity nearly always indicates hepatitis C viremia and suggest that viremia may be transient or fluctuating among some individuals who are nonreactive for hepatitis C virus antibodies by the recombinant immunoblot assay.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381382

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

Review 1.  Immunodiagnosis of viral hepatitides A to E and non-A to -E.

Authors:  G Yang; G N Vyas
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

2.  Epidemiology, serological markers, and hepatic disease of anti-HCV ELISA-2-positive blood donors.

Authors:  F J Salmerón; A Palacios; M Pérez-Ruiz; C Torres; S Oyonarte; A Fernández-Montoya; A Ruiz-Extremera
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

3.  Detection of hepatitis C virus by PCR in second-generation enzyme immunoassay-seropositive blood donors by using matched pairs of fresh frozen plasma and pilot tube sera.

Authors:  M Krajden; J Zhao; C Bourke; V Scalia; P Gill; W Lau
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

4.  Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts.

Authors:  M Adams; L Sharmeen; J Kimpton; J M Romeo; J V Garcia; B M Peterlin; M Groudine; M Emerman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

5.  A study-screening of blood donors for blood transmissible diseases.

Authors:  S V Shinde; G V Puranik
Journal:  Indian J Hematol Blood Transfus       Date:  2008-03-19       Impact factor: 0.900

6.  Flow cytometric immunodetection of human immunodeficiency virus type 1 proviral DNA by heminested PCR and digoxigenin-labeled probes.

Authors:  G Yang; S Garhwal; J C Olson; G N Vyas
Journal:  Clin Diagn Lab Immunol       Date:  1994-01

7.  Hepatitis C virus genotypes in Korea and their relationship to clinical outcome in type C chronic liver diseases.

Authors:  C J Han; H S Lee; H S Kim; J H Choe; C Y Kim
Journal:  Korean J Intern Med       Date:  1997-01       Impact factor: 2.884

8.  Assessment of viral genotype impact to the cost-effectiveness and overall costs of care for PEG-interferon-2α + ribavirine treated chronic hepatitis C patients.

Authors:  Mihajlo Jakovljevic; Zeljko Mijailovic; Biljana Popovska Jovicic; Predrag Canovic; Olgica Gajovic; Mirjana Jovanovic; Dejan Petrovic; Olivera Milovanovic; Natasa Djordjevic
Journal:  Hepat Mon       Date:  2013-06-19       Impact factor: 0.660

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.